0001104659-21-006328.txt : 20210121 0001104659-21-006328.hdr.sgml : 20210121 20210121163124 ACCESSION NUMBER: 0001104659-21-006328 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210120 FILED AS OF DATE: 20210121 DATE AS OF CHANGE: 20210121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Smith L. Mary CENTRAL INDEX KEY: 0001787013 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39044 FILM NUMBER: 21542368 MAIL ADDRESS: STREET 1: C/O SPRINGWORKS THERAPEUTICS, INC. STREET 2: 100 WASHINGTON BLVD. CITY: STAMFORD STATE: CT ZIP: 06902 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SpringWorks Therapeutics, Inc. CENTRAL INDEX KEY: 0001773427 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 WASHINGTON BOULEVARD CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-883-9490 MAIL ADDRESS: STREET 1: 100 WASHINGTON BOULEVARD CITY: STAMFORD STATE: CT ZIP: 06902 4 1 tm213781d2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-01-20 0 0001773427 SpringWorks Therapeutics, Inc. SWTX 0001787013 Smith L. Mary C/O SPRINGWORKS THERAPEUTICS, INC. 100 WASHINGTON BLVD. STAMFORD CT 06902 0 1 0 0 Chief Development Officer Common Stock 2021-01-20 4 M 0 1128 1.65 A 168639 D Common Stock 2021-01-20 4 M 0 8872 2.30 A 177511 D Common Stock 2021-01-20 4 S 0 10000 78.7016 D 167511 D Stock Option (Right to Buy) 1.65 2021-01-20 4 M 0 1128 0 D 2029-03-19 Common Stock 1128 1451 D Stock Option (Right to Buy) 2.30 2021-01-20 4 M 0 8872 0 D 2029-04-22 Common Stock 8872 114296 D The stock option exercises and sale transactions reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $77.83 to $79.24, inclusive. Includes 167,511 restricted stock awards which are subject to forfeiture until they vest. 25% of this option vested and became exercisable on March 19, 2020. The remainder vests and becomes exercisable in 36 equal monthly installments thereafter. This option began to vest and become exercisable in 48 equal monthly installments beginning on April 22, 2019. /s/ Francis I. Perier, Jr as Attorney-in-Fact 2021-01-21